In this video, Dr. Dan reviews a number of previous videos briefly as they apply to the consideration of the importance and role of biomarkers in the first line therapy for gastroesophageal adenocarcinoma. This overview video sets the stage for the next series of videos for the 4 main biomarker categories for first line therapy (HER2+, PDL1+, Claudin18.2+, and 'triple' negative). Additionally, an introduction of the NCCN guidelines is provided, in terms of what they are, how they are derived, and how they are used, along with comparing and contrasting the NCCN guidelines with FDA approvals of therapies.

For online second opinions for patients in or visiting Illinois, please visit: catenacciconsulting.com

свернуть